Do you have a research project that would benefit from comprehensive high sensitivity analysis of protein biomarkers in blood?
The Parkinson’s Disease Grant Program will award three (3) research projects with analysis of 86 samples using the NULISAseq™ Neuro 220 Panel through Alamar’s Technology Access Program.
The NULISAseq™ Neuro 220 Panel offers comprehensive coverage of the Hallmarks of Neurodegenerative disease with highly sensitive and specific multiplexed analysis of 220 biomarkers from biofluids, including 25 new biomarkers associated with Parkinson’s Disease, 15 of which were developed with support from The Michael J. Fox Foundation for Parkinson’s Research, providing researchers with an automated solution to dissect heterogeneity and identify signatures of disease initiation and progression in clinical cohorts.
- Biomarker Discovery: Identify novel biomarkers associated with Parkinson’s Disease by measuring a wide range of proteins simultaneously in different disease states and compare them to healthy controls.
- Drug Development and Clinical Trials: Evaluate the effects of potential therapeutic agents on specific protein targets related to inflammation and assess their efficacy in preclinical and clinical studies.
- Diagnostic Development: Measure specific protein markers known to be associated with the presence and severity of diseases and differentiate between different subtypes or stages of a particular disease.
Submit your grant proposal:
Visit funding web page
(https://alamarbio.com/alamar-parkinsons-grant-program)
